Objective:To observe the clinical efficacy of Qici Sanling Decoction combined with Pirarubicin in the treatment of non-muscle invasive bladder cancer. Methods100 TUR-BT postoperative patients with non-muscle invasive bladder cancer were randomly divided into the treatment group(66 cases) and control group(34 cases). The control group was treated with Pirarubicin by intravesical instillation and the treatment group was orally treated with Qici Sanling Decoction based on the treatment for the control group,with a course of 1 year,and the patients were followed-up for 1 year after treatment. The tumor recurrence and medication safety were observed. The changes on correlative symptoms,life quality scale(QLQ-C30 and QLQ-BLS24 sub-scales),immune function indexes such as NK cells,CD4,+, and CD8,+, were compared.  Results:①Within 1 year after treatment,the recurrence rates were 15.6% in the treatment group and 25.0% in the control group,the recurrence rate in the treatment group was obviously lower than that in the control group(P,<,0.05). ②After treatment,there were statistically significant differences on the scores of fatigue,pain,insomnia,constipation,physical function,emotional function and overall health condition between the two groups,and the improvement in the treatment group was obviously better than that in the control group(P,<,0.05). ③After treatment,there were statistically significant differences on the scores of urination symptoms,intestinal symptoms,treatment relative problems and sexual life quality between the two groups,and the improvement in the treatment group was obviously better than that in the control group(P,<,0.05). ④After treatment,there were statistically significant differences on the levels of NK cells,CD,4+, and CD,8+, between the two groups,and the improvement in the treatment group was obviously better than that in the control group(P,<,0.05). ⑤There was no statistically significant difference on the incidence rate of adverse reactions between the two groups(P,>,0.05).  Conclusion:Qici Sanling Decoction combined with Pirarubicin in treating postoperative patients with non-muscle invasive bladder cancer can significantly reduce the cancer recurrence rate,enhance the systemic immunity,alleviate the side effects caused by chemotherapy drug instillation and improve the overall quality of life.